Cronos Group
- Market cap
- 1.19B
- P/E (TTM)i
- 17.05
- P/Bi
- 1.12
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 72%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Cronos Group (CRON) | 1.19B | 17.05 | 1.12 | 0.00% |
| Takeda Pharmaceutical (TAK) | 58.68B | -55.67 | 1.23 | 3.26% |
| Teva Pharmaceutical Industries (TEVA) | 45.70B | 65.30 | 5.89 | 0.00% |
| Haleon (HLN) | 39.67B | 18.87 | 1.83 | 2.11% |
| Zoetis (ZTS) | 29.57B | 11.67 | 9.39 | 2.88% |
| United Therapeutics (UTHR) | 23.38B | 19.53 | 3.65 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 11.6% below Morningstar's fair value estimate.
Fair value
Cronos Group Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $3.61 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 89.4%, which lies in the top 40% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.
Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 14.6%, a core component of profitability, sits in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.
By Quantitative Equity Report
Quote time 2026-10-08 05:42:01 · For reference only, not investment advice and not tailored to your situation.